Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Amble Tirzepatide Review: Cost & Honest Verdict (2026)

An honest 2026 review of Amble tirzepatide — nationwide compounded GLP-1 access, a starting-dose price, and thin public program detail.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

System Labs

A flat $179/month tirzepatide subscription at every dose, from a company that names three physicians and no pharmacy.

$179/mo flat ($99 first month)

Check System Labs availability

Amble is a telehealth weight-loss provider offering compounded semaglutide and tiered tirzepatide programs, serving all 50 states. Every fact here comes from the company's own published program.

What Amble is

Amble is a telehealth weight-loss provider, offering compounded semaglutide and tiered tirzepatide programs across all 50 states. An online intake is reviewed by a licensed clinician, and Amble publishes its price before you start the intake.

§ Amble — What's Confirmed

SignalStatus
Tirzepatide price$289/mo, starting dose
CoverageAll 50 states
Program detailLimited — clinicians/pharmacy not disclosed
Verified: $289/month starting price, all 50 states served. Limited public information on clinicians and pharmacy partners.

What Amble costs

Compounded tirzepatide starts at $289/month — a starting-dose figure, so confirm what a titrated dose costs before assuming it stays flat.

The brand-vs-compounded question

Amble dispenses compounded tirzepatide, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Amble's real strengths: both semaglutide and tirzepatide available, and coverage across all 50 states. The trade-off is disclosure: this review, like prior research, found limited public information about the program's clinicians, pharmacy partners, or overall structure beyond the pricing and state coverage. As with any GLP-1 program, ask directly about the compounding pharmacy and the price at your expected dose before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Amble offers nationwide compounded access at a competitive starting price, but this review found limited public detail on its clinicians and pharmacy partners — ask directly before committing. If you want a provider with more disclosed program detail, compare it against Alternate Health Club or bmiMD; and if you'd rather see a real medspa's physical address behind your provider, weigh AquaVita NextGen. AZ Health is a similarly transparent-on-price, thin-on-legal-disclosure option worth comparing too. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

How much does tirzepatide cost through Amble?

$289/month — a starting-dose figure.

Which states does Amble serve?

All 50 states.

Does Amble name its compounding pharmacy?

No — this review found limited public information about Amble's clinicians or pharmacy partners beyond the pricing and state coverage.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.